Syros Pharmaceuticals, Inc.

Good morning and welcome to Cirrus Pharmaceuticals' second quarter 2023 financial results conference call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of Cirrus' website at www.cirrus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Karen Hanady, Director of Investor Relations and Corporate Communications at Cirrus. Please go ahead.

Thank you. This morning, we issued a press release announcing our second quarter 2023 financial results. The full release is available on the Investors and Media section of Cirrus' website at www.cirrus.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristen Stevens, our Chief Development Officer, Dr. Eric Olson, our Chief Scientific Officer, and Conley Chee, our Chief Commercial Officer, are also on the call and will be available for Q&A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our quarterly report on Form 10-Q that we filed this morning, our annual report on Form 10-K that we filed earlier in the year, and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. I would now like to turn the call over to Nancy. Nancy.

Thank you, Karen. Good morning, everyone, and thank you for joining us today. The first half of the year has been very productive for Cirrus, and we are encouraged by ongoing momentum across our clinical trials and our pre-commercial activities. We remain laser focused on clinical trial execution and are well positioned to achieve each of our upcoming milestones with data readouts from our phase two study evaluating tamiberitine and newly diagnosed unfit AML expected in the fourth quarter of 2023, and from our pivotal phase three trial of tamiberitine and higher risk MDS expected in the third quarter of 2024, and an update on PK data and registration plans for SY-2101 and APL expected in the second half of this year. As we execute against our clinical development plans and approach data readouts, we are engaging in pre-commercial activities to ensure that we are well positioned to effectively deliver our novel treatments to patients. We believe the potential of our biologically targeted programs in MDS, AML, and APL, coupled with their commercial synergies, position us for substantial long-term success. with the opportunity to fulfill key unmet needs in the frontline treatment of hematologic malignancies and ultimately deliver new standards of care to thousands of patients in need. I would now like to turn the call over to David, our Chief Medical Officer, to provide a more detailed update on our ongoing clinical programs. David?